Analysts’ Weekly Ratings Changes for MacroGenics (MGNX)

MacroGenics (NASDAQ: MGNX) recently received a number of ratings updates from brokerages and research firms:

  • 2/13/2018 – MacroGenics was upgraded by analysts at Zacks Investment Research from a “sell” rating to a “hold” rating. According to Zacks, “MacroGenics Inc. is a biopharmaceutical company. It is focused on discovering and developing innovative monoclonal antibody-based therapeutics. The Company has a diverse portfolio of product candidates focused in three therapeutic areas: oncology, autoimmune disorders and infectious diseases. MacroGenics Inc. is headquartered in Rockville, Maryland. “
  • 2/13/2018 – MacroGenics was upgraded by analysts at BidaskClub from a “sell” rating to a “hold” rating.
  • 2/6/2018 – MacroGenics was downgraded by analysts at Zacks Investment Research from a “hold” rating to a “sell” rating. According to Zacks, “MacroGenics Inc. is a biopharmaceutical company. It is focused on discovering and developing innovative monoclonal antibody-based therapeutics. The Company has a diverse portfolio of product candidates focused in three therapeutic areas: oncology, autoimmune disorders and infectious diseases. MacroGenics Inc. is headquartered in Rockville, Maryland. “
  • 1/25/2018 – MacroGenics was upgraded by analysts at BidaskClub from a “strong sell” rating to a “sell” rating.
  • 1/24/2018 – MacroGenics had its “buy” rating reaffirmed by analysts at Cowen Inc.
  • 1/23/2018 – MacroGenics had its “buy” rating reaffirmed by analysts at SunTrust Banks, Inc.. They now have a $31.00 price target on the stock.
  • 1/23/2018 – MacroGenics had its “buy” rating reaffirmed by analysts at BTIG Research. They now have a $28.00 price target on the stock.
  • 1/11/2018 – MacroGenics was downgraded by analysts at BidaskClub from a “sell” rating to a “strong sell” rating.
  • 1/11/2018 – MacroGenics was upgraded by analysts at Zacks Investment Research from a “sell” rating to a “hold” rating. According to Zacks, “MacroGenics Inc. is a biopharmaceutical company. It is focused on discovering and developing innovative monoclonal antibody-based therapeutics. The Company has a diverse portfolio of product candidates focused in three therapeutic areas: oncology, autoimmune disorders and infectious diseases. MacroGenics Inc. is headquartered in Rockville, Maryland. “
  • 1/5/2018 – MacroGenics was upgraded by analysts at BidaskClub from a “strong sell” rating to a “sell” rating.
  • 1/3/2018 – MacroGenics was downgraded by analysts at Zacks Investment Research from a “hold” rating to a “sell” rating. According to Zacks, “MacroGenics Inc. is a biopharmaceutical company. It is focused on discovering and developing innovative monoclonal antibody-based therapeutics. The Company has a diverse portfolio of product candidates focused in three therapeutic areas: oncology, autoimmune disorders and infectious diseases. MacroGenics Inc. is headquartered in Rockville, Maryland. “

MacroGenics Inc (NASDAQ:MGNX) opened at $23.85 on Thursday. MacroGenics Inc has a 1-year low of $14.36 and a 1-year high of $23.93. The company has a market cap of $878.22, a PE ratio of -5.31 and a beta of 2.79.

In other news, SVP Jon Marc Wigginton sold 5,000 shares of the company’s stock in a transaction dated Wednesday, January 17th. The shares were sold at an average price of $20.00, for a total transaction of $100,000.00. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, SVP Eric Blasius Risser sold 3,000 shares of the company’s stock in a transaction dated Wednesday, January 24th. The shares were sold at an average price of $22.50, for a total transaction of $67,500.00. Following the sale, the senior vice president now owns 12,100 shares in the company, valued at $272,250. The disclosure for this sale can be found here. Insiders have sold a total of 13,000 shares of company stock valued at $267,500 in the last three months. Insiders own 8.30% of the company’s stock.

MacroGenics, Inc is a clinical-stage biopharmaceutical company focused on discovering and developing monoclonal antibody-based therapeutics for the treatment of cancer, as well as various autoimmune disorders and infectious diseases. The Company develops therapeutic product candidates using its antibody-based technology platforms and also in collaboration with other biopharmaceutical companies.

Receive News & Ratings for MacroGenics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MacroGenics Inc and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply